- Business Wire•4 hours agoCORRECTING and REPLACING Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium
First bulletpoint should read as "Study of lanreotide depot..."
- Reuters•10 days ago
The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsen's portfolio, which has traditionally focused on endocrinology. Ipsen will pay $575 million at the closing of the deal and up to $450 million more, contingent on some approvals for Onivyde in the United States.
- PR Newswire•10 days ago
The transaction, which is expected to be completed in the first quarter of 2017, is subject to certain customary closing conditions, including Merrimack stockholder approval and certain governmental regulatory clearances. Merrimack also today announced the completion of its previously announced strategic pipeline review resulting in the identification of the three most promising clinical programs to focus its development efforts on going forward.
IPN.PA : Summary for IPSEN - Yahoo Finance
Ipsen S.A. (IPN.PA)
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||53.26 x 46200|
|Ask||53.99 x 2000|
|Day's Range||72.35 - 73.06|
|52 Week Range||45.31 - 74.77|
|PE Ratio (TTM)||25.94|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|